Molecular partners signs development agreement with Eckert & Ziegler for targeted alpha radiotherapeutics

CAR-T Digest - August 2020

26 February 2026: Molecular partners signs development agreement with Eckert & Ziegler for targeted alpha radiotherapeutics

Molecular Partners announced a development agreement with Eckert & Ziegler to support the advancement and manufacturing of its targeted alpha radiotherapeutics, expanding the capabilities of its wholly owned Radio-DARPin pipeline
The partnership enables the development of Radio-DARPins incorporating Actinium-225 and Lutetium-177 payloads, complementing the company’s existing collaboration for Lead-212, and strengthening its strategy to precisely match therapeutic isotopes with tumor biology
Under the non-exclusive agreement, Eckert & Ziegler will provide development services leveraging its radiochemistry expertise and dedicated alpha-emitter infrastructure, including its specialized Alpha Laboratory in Berlin, to support preclinical and future clinical-stage programs
Molecular Partners is advancing multiple Radio-DARPin candidates, including its lead program MP0712 targeting DLL3, which has recently entered a Phase 1/2a trial in patients with small cell lung cancer, highlighting the growing momentum of its radiopharmaceutical portfolio
By combining DARPin-based targeting technology with specialized isotope manufacturing capabilities, the collaboration aims to accelerate the development of next-generation radiotherapies designed to deliver highly precise and potent tumor-directed treatment options